Pulmonary edema refers to the fluid accumulation in the air sacs (alveoli) and lung tissues. It occurs when small blood vessels (capillaries) that surround the air sacs become damaged or leak fluid. Common causes of pulmonary edema include heart failure, pneumonia, lung conditions like acute lung injury, and high altitude cerebral edema. The currently available pulmonary edema therapeutics are diuretics, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, and other drugs. They help manage symptoms by reducing excess fluid in the lungs and improving oxygen exchange.
The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The increasing patient population suffering from pulmonary edema presents a major market opportunity. As per estimates, over 6 million Americans suffer from heart failure each year, which is one of the leading causes of pulmonary edema. Moreover, other conditions like pneumonia also lead to pulmonary edema in a substantial number of patients globally each year. With rising risk factors like pollution, tobacco smoking, and lifestyle diseases, the prevalence of these conditions is projected to grow further. Therefore, the need for effective therapeutic drugs and treatments for pulmonary edema will continue to rise steadily over the forecast period. This growing patient pool will drive significant demand for newer and more efficacious pulmonary edema therapeutics during the same time period.
Porter's Analysis
Threat of new entrants: The threat of new entrants in the pulmonary edema therapeutics market is low due to the capital required for R&D of new drugs and the regulations imposed by the FDA.
Bargaining power of buyers: The bargaining power of buyers is moderate due to availability of generic drugs. However, branded drugs give doctors more confidence in treatment effectiveness.
Bargaining power of suppliers: The bargaining power of suppliers is low due to presence of many raw material suppliers for pulmonary edema drugs.
Threat of new substitutes: There is low threat of new substitutes as pulmonary edema has limited treatment options currently available.
Competitive rivalry: Competition in the market is high between major players.
SWOT Analysis
Strength: Existing drugs have established efficacy and safety profiles supported by clinical data. Growing aging population is increasingpatient pool suffering from pulmonary edema.
Weakness: High development cost of new drugs. Existing drugs have shortcomings such as side effects.
Opportunity: Untapped developing markets hold huge market potential. Novel drug delivery approaches can improve treatment effectiveness and compliance.
Threats: Generic competition erodes sales of branded drugs. Stringent regulatory environment for new drug approvals.
Key Takeaways
The Global Pulmonary Edema Therapeutics Market is expected to witness high growth over the forecast period of 2023 to 2030. The market size for 2023 is estimated to be US$ 12144.1 Mn.
North America include growing elderly population, unhealthy lifestyle habits, increasing incidence of congestive heart failure, and technological advancements. The Asia Pacific region is expected to witness the fastest CAGR during the forecast period due to rising cases of pulmonary edema along with developing healthcare infrastructure and improving access in major Asian countries.
Key players operating in the pulmonary edema therapeutics market include Crayola LLC, Faber-Castell AG, Sargent Art, Reeves (Colart Group), Liquitex (Colart Group), Sax Arts & Crafts, Prang (Dixon Ticonderoga Company), RASCHER GmbH, Richeson Art Materials, Jovi S.L. Major players focus on new drug development and collaborations to strengthen their product portfolios and market positions.
For more details on the report, Read- https://www.insightprobing.com/pulmonary-edema-therapeutics-market-demand-share-analysis/
Market HighlightsIncreasing prevalence of pulmonary edema and diseases like kidney failure, heart diseases, and others along with the growing geriatric population boosts the market growth.
On the other hand, low per capita healthcare expenditure in the middle and low-income countries, and lack of awareness about the disease are estimated to restrain the market growth.The global pulmonary edema market is expected to grow at an approximate CAGR of 7.2% during the forecast period.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/5607SegmentationThe global pulmonary edema market is segmented on the basis of type, diagnosis, treatment, and end user.
The blood tests segment is sub-segmented into b-type natriuretic peptide (BNP), blood count test, kidney function test, and others.
On the basis of the treatment, the market is segmented into preload reducers, morphine, suction catheter, and others.
The preload reducers segment is sub-segmented into nitroglycerin, diuretics, and others.
On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, retail pharmacies, and others.Regional AnalysisAmerica dominates the global pulmonary edema market due to the presence of a well-developed healthcare sector, high per capita healthcare expenditure and developed economies such as the U.S. and Canada within the region.
